AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Feature|Articles|September 2, 2026
Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS
Author(s)Lexi Cogswell, PhD, Tom Rotolo, PhD
Real-world evidence tells you what happened. Real-World iNSIGHTS tell you why — and what to do next. A new framework for medical affairs.
Advertisement
Advertisement
As the healthcare community grapples with rising obesity rates, medical strategy generation is undergoing its most significant evolution in decades, moving away from a traditional model of data dissemination toward a future defined by strategic intelligence. To meet the challenges of this complex therapeutic area, pharmaceutical organizations must look beyond traditional data sources and embrace a new way: supporting the generation of Real-World iNSIGHTS.
Related to this article
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
Advertisement
Advertisement